advertisement
Abstract #25423 Published in IGR 12-1
Central corneal thickness during treatment with travoprost 0.004% in glaucoma patients
Schlote T; Tzamalis A; Kynigopoulos MJournal of Ocular Pharmacology and Therapeutics 2009; 25: 459-462
Purpose: Experimental studies demonstrated an alteration of corneal collagen structure by prostaglandin analogues. The possible effect of the prostaglandin F(2) analogue travoprost 0.004% on the central corneal thickness (CCT) in newly diagnosed glaucoma patients was evaluated. Methods: Consecutive, interventional case series. Seventy-four patients/136 eyes with glaucoma were included in the statistical analysis. All patients received travoprost 0.004% (Travatan(registered trademark)) once daily in one or both eyes. CCT was measured by using noncontact optical low-coherence reflectometry prior to the treatment and after 6 and 12 months. Results: Mean CCT of all treated eyes (n = 136) was 546.71 (plus or minus) 34.63 m at baseline, 535.14 (plus or minus) 34.78 m after 6 months, and 532.38 (plus or minus) 34.18 m after 12 months (ANOVA, P < 0.001). Ninety-five percent of all treated eyes showed a decrease of CCT. CCT reduction mainly developed within the first 6 months of the treatment period. After 12 months, a CCT reduction >30 m occurred in 5.1% of all treated eyes. There was a significant correlation between the magnitude of corneal thinning and the initial CCT but not between corneal thinning and IOP reductions. Conclusions: Topical therapy with the prostaglandin derivate travoprost is accompanied by a significant reduction of CCT within one year of treatment. Further clinical studies are needed to evaluate the possible long-term effects of prostaglandins on the CCT of glaucoma patients.
T. Schlote. Clinic of Ophthalmology Ambimed, Klingentalstrasse 9, Basel 4057, Switzerland. tschlote@bluewin.ch
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
2.2 Cornea (Part of: 2 Anatomical structures in glaucoma)
